# An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

> **NCT06625398** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Viridian Therapeutics, Inc.** · enrollment: 195 (estimated)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** VRDN-003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06625398
- **Lead sponsor:** Viridian Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-27
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-12-15
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625398, "An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06625398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*